Her2+

Is there any data on the efficacy of T-Dxd after progression on sacituzumab govitecan? Does your approach differ by hormone receptor status now that ...

4 Answers available

Would a HER2 mutation on NGS of a biopsy of a breast cancer liver metastasis change your management if the met is HER2- by IHC with the initial localized disease being HER2+?

If NGS was positive would you treat with HER2 directed therapy? How, if at all, would you incorporate T-DXd into this treatment paradigm?

5 Answers available

Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?

She achieved PCR with NAC with TCHP and is now on adjuvant HP.

2 Answers available

How would you approach post-operative radiation in a patient with ER/PR negative Her2 positive, T1c N0 breast cancer originating in the ectopic mammary tissue close to the axilla, treated wide excision followed by APT regimen (weekly paclitaxel plus trastuzumab with trastuzumab for one year)?

1 Answer available

What alternative regimens would you consider to neoadjuvant TCHP in setting of national carboplatin shortage for locally advanced HER2+ breast cancer?

1 Answer available

Would you recommend olaparib for a patient with germline BRCA1 mutation and HER2+ metastatic breast cancer who has progressed through multiple lines of HER2-directed therapy including trastuzumab deruxtecan?

Does your approach differ across the HER2 IHC spectrum?

4 Answers available

Would you include HER2 directed therapy in the treatment of HER2+ small bowel adenocarcinoma?

1 Answer available

Do you test your esophageal and gastric specimens for HER2 using IHC, FISH, or both?

What other molecular tests do you routinely order on such tumors?

5 Answers available

How would you continue management of a patient with clinical stage II cN+ HR+ HER2+IDC with grade 3 diarrhea after 1 cycle of neoadjuvant TCHP?

2 Answers available

Would you consider use of T-DXd for metastatic gastric/GEJ cancers with "HER2 low" given emerging data in the breast cancer setting?

3 Answers available

How do you consider first and subsequent lines of treatment sequencing in metastatic gastric/GEJ cancer that is both HER2+ and CPS>5?

3 Answers available

How do you decide on 2nd line therapy in a patient with HER2+ metastatic esophageal/gastric cancer who progresses after initial response to trastuzumab-based chemotherapy?

Are there factors that would lead you to select either ramucirumab +/- paclitaxel vs T-Dxd vs chemo?

6 Answers available

How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

5 Answers available

In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?

2 Answers available

When do you consider HER2-targeting antibody drug conjugates in the first line setting for metastatic HER2 positive, ER negative breast cancer?

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...

5 Answers available

How would you approach a young patient with a prior ER+ HER2- breast CA now local recurrence that now has Her2 positive disease?

If a patient previously received taxane-based chemotherapy for the initial cancer, is additional chemotherapy recommended or can HER2-directed and hor...

1 Answer available

How would you manage tucatinib-associated grade 2 indirect hyperbilirubinemia in a patient with metastatic HER2-positive breast cancer involving the CNS receiving trastuzumab + capecitabine + tucatinib?

Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...

2 Answers available

What adjuvant therapy would you offer an elderly but healthy patient with T2N1 HR+ HER2+ breast cancer who is not willing to receive cytotoxic chemotherapy?

1 Answer available

What adjuvant systemic therapy would you recommend for a woman s/p ALND for a nodal recurrence of ER-/HER2+ breast cancer 1 year after completing adjuvant therapy with paclitaxel/trastuzumab for her initial disease?

At initial diagnosis she had T1cN0 disease treated with lumpectomy and SLNB followed by 12 weeks of paclitaxel with 1 year of trastuzumab.

4 Answers available

What neoadjuvant regimen would you give a patient with multicentric IDC consisting of TNBC and concurrent ER/PR- HER2+ breast cancer with ER/PR- HER2+ axillary LN mets?

2 Answers available

When, if ever, will you utilize T-DM1 in metastatic HER2+ breast cancer given trastuzumab deruxtecan's significantly improved PFS vs T-DM1?

The FDA recently approved trastuzumab deruxtecan (T-DXd) in the second line setting. Given the results of DESTINY-Breast03, what is now the role of TD...

5 Answers available

How would you approach a locally recurrent HER2 positive breast cancer patient previously treated with TCHP, lumpectomy, and a year of adjuvant TDM-1?

Patient was initially ER positive, HER2 positive. Currently she is on letrozole. Recurrence is ER/PR negative and HER2 positive and developed almost 2...

1 Answer available

If a patient with HER2+ uterine serous carcinoma recurs while on maintenance trastuzumab, would you continue trastuzumab with second line chemotherapy?

Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.

2 Answers available

Would you use T-DXd or capecitabine/trastuzumab/tucatinib for HER2+ metastatic breast cancer with predominantly CNS progression after THP?

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?

3 Answers available

What treatment would you provide for a patient with bilateral synchronous locally advanced cT4dN0 TNBC and cT1b ER+ HER2+ breast cancer?

Would you proceed with KEYNOTE 522 regimen and add anti-HER2 targeted therapy adjuvantly?

2 Answers available

How would you adjust therapy for a HER2+ breast cancer patient found to have elevated LFTs while on TCHP?

What do you do if LFTs are elevated after one dose of neoadjuvant TCHP (highest ALT >13 times upper limit of normal, normal bilirubin) with prior n...

1 Answer available

For a patient with metastatic gastric adenocarcinoma with CT showing NED after 4 months of FOLFOX + pembrolizumab + trastuzumab, would you consider resection of the primary and/or a chemo break?

Would your thinking change if the patient continues to be NED after an unplanned chemo break, e.g. for insurance issues?

2 Answers available

How would you approach a patient who has developed neutropenia with the combination of trastuzumab/pertuzumab in the adjuvant setting?

Would you consider the discontinuation of either anti-HER2 agent or both?

1 Answer available

Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?

Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts? Are ther...

2 Answers available

Would you give chemotherapy and trastuzumab to a patient with multifocal high grade, microscopic (<5mm) HR-, HER2+ IDC embedded in extensive DCIS, staged as pTis pT1a(m) N0?

1 Answer available

How would you approach treatment of a patient with metastatic NSCLC with PD-L1>1% and HER2-mutation?

Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...

3 Answers available

Based on KEYNOTE-811, would you add pembrolizumab for HER2+ distal esophageal adenocarcinoma with new supraclavicular lymph nodes if treated previously with concurrent chemoradiation and PD-L1 CPS of 3?

2 Answers available

What maintenance therapy, if any, do you offer patients with metastatic HER2+ esophageal or gastric cancer?

What combination of fluoropyrimidine, PD-1 inhibitor, or trastuzumab do you use?

1 Answer available

In a patient with metastatic HER2 positive breast cancer who has received prior TDM1 in the adjuvant setting for residual disease, would you consider reintroduction of TDM1?

The patient is intolerant to trastuzumab deruxtecan. In which clinical settings would you consider reintroduction of TDM1?

1 Answer available

Would you offer immunotherapy in addition to chemotherapy and trastuzumab for patients with metastatic HER2 positive gastroesophageal cancer with low PDL1?

KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.

1 Answer available

In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP?

Patient is ypT2N1

1 Answer available

How would you approach systemic therapy for a pre-menopausal woman with ER+/PR+/HER2 positive breast cancer who had a local recurrence 6 months after completing adjuvant TCH and a year of trastuzumab + tamoxifen?

Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+...

1 Answer available

How do you interpret efficacy of trastuzumab deruxtecan based on HER2 mutation type and/or level of HER2 overexpression?

How and when do you plan to perform HER2 testing in patients with NSCLC?

2 Answers available

Do you find data from phase 2 DESTINY-LUNG01 study sufficient to change practice in HER2 mutant NSCLC or is a phase 3 study still needed?

How does trastuzumab deruxtecan compare to other HER2 targeted strategies?

3 Answers available

What is your approach to a patient with metastatic lung cancer with HER2 mutant NSCLC who is not a trial candidate?

How are you thinking about sequencing therapies for these patients (IO vs chemo vs T-Dxd)? Are the data from DESTINY-Lung01 strong enough to warrant e...

3 Answers available

What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use? Do you feel the dosing used in...

2 Answers available

How would you manage adjuvant treatment of a premenopausal woman with HER2 positive, ER/PR negative multifocal micro-invasive node-negative breast cancer?

Largest invasive focus is 0.4mm

1 Answer available

Is there a role for extended adjuvant neratinib with pCR after neoadjuvant chemotherapy in triple positive breast cancer?

1 Answer available

With advancing and new therapies emerging for metastatic HER2+ breast cancer, how does one decide between options for third line therapy at time of progression?

2 Answers available

How do you treat metastatic HER2 positive breast cancer in a patient with hepatic visceral crisis?

The patient has extensive liver metastases and a high bilirubin. She has not received any prior systemic therapy in the metastatic setting.

2 Answers available

What treatment options would you provide a HER2+/HR+ patient with significant residual disease s/p TCHP if they go on to develop severe neuropathy following adjuvant T-DM1 therapy?

Patient had an initial tumor response to TCHP, but still had significant residual disease present, including positive lymph nodes and residual breast ...

1 Answer available

How do you approach the treatment of de novo, brain only metastatic HER2 positive breast cancer?

1 Answer available

Would you consider adding HER2 targeted treatment to chemotherapy for a patient with locally advanced, HER2+ rectal cancer who is going to have total neoadjuvant treatment?

3 Answers available

How would you manage adjuvant therapy for a premenopausal female with a T1cN1mi breast IDC that is HR+ HER2 positive on biopsy, but HR+ HER2 negative on lumpectomy surgical specimen?

<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...

2 Answers available

How would you treat HR positive, HER2 positive metastatic breast cancer in patients with a borderline or poor performance status?

1 Answer available

How would you modify adjuvant therapy for a patient with ER+ HER2+ breast CA with no response to neoadjuvant TCHP and develops pneumonitis on adjuvant TDM-1?

Would you use trastuzumab/pertuzumab, trastuzumab followed by neratinib, or another strategy?

1 Answer available

What adjuvant systemic therapy would you offer to a healthy elderly woman with a 5mm, node negative, grade 2 HR+HER2+ invasive lobular carcinoma?

Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?

4 Answers available

How would you manage a patient with early stage ER+ HER2+ breast CA who cannot receive definitive local therapy due to severe cardiopulmonary co-morbidities?

How would your plan differ if the patient could eventually receive mastectomy once co-morbidities improve?

1 Answer available

What is your approach for endocrine therapy in young women (<35 years old) with HR+/HER2+ breast CA with residual disease after TCHP who will start adjuvant T-DM1?

3 Answers available

What would you recommend as the next line treatment in a post-menopausal woman with hormone receptor positive, HER2 positive breast cancer, with progression on T-DM1 in combination with aromatase inhibitor?

1 Answer available

Which adjuvant chemotherapy regimen would you recommend for a peri-menopausal woman with synchronous stage IA primary breast tumors, one that is ER+HER2+ and the second ER+HER2-?

1 Answer available

How does clinical intramammary lymph node involvement in HER2+ breast cancer affect your neoadjuvant chemotherapy choice?

Would you prefer TCHP over TCH? Would you consider adding an anthracycline?

1 Answer available

How do you manage a HR-/HER2+ breast cancer patient with local progression during neoadjuvant TCHP?

How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?

1 Answer available

How do you approach a women with localized HER2+ breast cancer that was HER2+ by FISH but negative (0+) by IHC?

3 Answers available

Would you modify your initial treatment for a patient with de novo metastatic HR- HER2+ breast CA who has cardiomyopathy at baseline (EF < 35)?

Is there any safety data to proceed with TKIs/TDM-1 or to proceed as standard with THP?

1 Answer available

How long would you keep a patient on endocrine/dual anti HER-2 therapy after resection of a late (>5 years) oligometastatic recurrence of ER+ HER2+ breast CA?

For patients who remain NED for years, when would you feel it's appropriate to hold therapy?

1 Answer available

What systemic therapy would you choose for elderly patients with HER2+ breast CA who have early metastatic relapse (within months) of completing adjuvant trastuzumab/paclitaxel?

What would you offer if the patient is not a candidate for cytotoxic therapy?

1 Answer available

Do you routinely add endocrine therapy to anti-HER2 maintenance therapy after 6 cycles of THP for metastatic ER+ HER2+ breast CA?

1 Answer available

In what situations would you offer systemic therapy for HER2+ microinvasive invasive ductal carcinoma?

1 Answer available

Do you give adjuvant chemotherapy/trastuzumab to a premenopausal woman with a pT1aN0 HR+, Her2+ breast cancer?

3 Answers available

Would you give a HER2 targeted agent to a patient whose initial cancer was ER/PR positive, HER2 negative but now with metastatic disease that is ER positive, PR negative, HER2 2+, FISH equivocal?

Patient has progressed through prior lines of endocrine therapy.

1 Answer available

How would you manage adjuvant treatment of a patient with ER+/PR+/HER2+ breast cancer and a small amount of residual disease (e.g. T1mi) following neoadjuvant TCHP?

Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.

4 Answers available

What non-taxane chemotherapy, if any, would you give with trastuzumab in adjuvant setting of a pT1cN0 HER2+ breast CA in patients with hyperbilirubinemia >3 due to cirrhosis?

1 Answer available

Would you treat an ER/PR+ inflammatory breast cancer that is HER2 2+ by IHC but 5% positive by FISH as HER2 positive?

2 populations of cells with 95% negative by FISH (ratio 1.07) and 5% positive by FISH (ratio 10)

1 Answer available

Would you offer adjuvant TDM-1 to a patient with residual disease after neoadjuvant treatment for biopsy proven HER2 positive breast cancer, although residual tumor biopsy shows discordance with HER2 negative status?

4 Answers available

How do you manage ovarian suppression for premenopausal patients with HR+/HER2 positive breast cancer?

Does lymph node positivity change your management?

1 Answer available

Is it acceptable to use TCHP instead of AC-T + trastuzumab as neoadjuvant chemotherapy for HER2+ inflammatory breast cancer?

Patient case is triple positive inflammatory breast cancer

2 Answers available

Are docetaxel and paclitaxel interchangeable for stage II-III HER2+ breast cancer patients receiving neoadjuvant chemotherapy with AC-THP?

Are there any studies that compare them?

1 Answer available

Does ER+ status impact your choice of neoadjuvant systemic therapy in premenopausal women with cT2N0 HER2+ breast cancer?

How would your treatment change given pCR rates are reportedly much lower in triple positive patients?

3 Answers available

For a patient with isolated CNS recurrence of HR+HER2+ breast cancer after completion of adjuvant therapy, what, if any, systemic therapy would you start after completion of local therapy?

Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy.

2 Answers available

Is there a role for endocrine therapy alone in patients with metastatic HR+, HER2+ breast cancer after all HER2 directed therapies have been used?

1 Answer available

How do you approach the re-challenge with trastuzumab in metastatic HER2+ patients who develop cardiomyopathy on trastuzumab/pertuzumab with subsequent improvement with discontinuation?

Do you repeat the loading dose of trastuzumab?

1 Answer available

What second line treatment would you choose for a post menopausal woman with HR+ HER2+ metastatic breast cancer with low burden disease treated with first line aromatase inhibitor and trastuzumab?

1 Answer available

What adjuvant treatment would you recommend for a Stage I HER2 positive breast cancer with grade 3 neuropathy from previous taxane treatment?

5 Answers available

What systemic therapy would you consider, if any, for an isolated but multifocal CNS recurrence of HER2+ HR negative breast cancer treated with local therapy (>4 lesions treated with resection and SRS)?

Patient completed neoadjuvant therapy with TCH 2 years prior, and has no evidence of disease outside the CNS on PET/CT.

1 Answer available

What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?

Given the changing landscape of treatment, some patients may have already received capecitabine previously. Would this impact your treatment rec...

1 Answer available

How would you approach adjuvant treatment of an early stage HR+ HER2+ cancer if the patient had already been taking an aromatase inhibitor for a contra-lateral HR+ early stage breast cancer?

Interest in approach for elderly population especially

3 Answers available

How would you change the regimen for a patient receiving neoadjuvant TCHP or node positive HR+/HER2+ breast cancer who develops a severe allergic reaction to docetaxel?

Would you consider an anthracycline based substitution vs changing to nab-paclitaxel or a combination with platinum agent?

1 Answer available

How do you approach a stage IIIC triple positive IDC, s/p neoadjuvant TCH and P, lumpectomy, and ALND with significant residual disease at the time of surgery?

Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?

5 Answers available

How do you approach HER2 directed therapy with discrepant results between FISH and Oncotype?

Especially if HER2 negative on pathological specimen

1 Answer available

Would you hold pertuzumab around the time of surgery?

1 Answer available

How would you approach systemic therapy for a postmenopausal female with metastatic ER+/HER2+ breast cancer (liver/bone) who achieved a CR for 5 years on trastuzumab/pertuzumab and exemestane, with continued asymptomatic brain progression?

Asymptomatic brain progression despite CNS surgery and SRS x2 over the past 2 years.

1 Answer available

What is your approach to oligometastatic HER2 positive breast cancer, particularly after excellent clinical response in all sites of disease to trastuzumab, pertuzumab, and a taxane?

1 Answer available

In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?

2 Answers available

Would you consider adjuvant TDM-1 for a patient with HR+,HER2+ breast cancer with pCR in the breast but N1mic disease post neoaduvant chemotherapy?

N1mic - few isolated malignant cells in 1 axillary lymph node

1 Answer available

Do you ever stop pertuzumab for stable disease in a patient with metastatic, HER2 positive breast with stable disease?

In cases where patient received 6 cycles of THP and 1 year of HP

2 Answers available

How would you approach a patient with DCIS (ER/PR/HER2 negative) with microinvasion in a SLN that is HER2 positive?

1 Answer available

Would you use tucatinib in a patient with recurrent HER2+ breast cancer with isolated brain metastasis with leptomeningeal disease?

Patient received adjuvant chemotherapy and anti-Her2 therapy 3 years ago.

1 Answer available

Would weak PR positivity make you consider adjuvant endocrine therapy for a young pre-menopausal woman with a HER2 positive ER negative breast cancer?

If yes, would you offer tamoxifen or ovarian suppression plus AI?

1 Answer available

How would you approach a postmenopausal patient with HR-,HER2+ breast cancer who has oligometastatic disease, and is s/p complete resection of brain met with no other evidence of systemic disease?

Received adjuvant HER2 directed therapy 3 years ago.

1 Answer available

What is your strategy for a patient who develops an enlarging ipsilateral axillary lymph node shortly after undergoing mastectomy and ALND for a pT2N3 ER+/HER2+ right breast cancer?

This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...

1 Answer available

Do you recommend routine surveillance MRI brain for asymptomatic patients with metastatic HER2+ breast cancer?

1 Answer available

How would you approach a patient with HR+, HER2- metastatic breast cancer who is endocrine resistant, with bone marrow involvement and pancytopenia?

How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...

5 Answers available

For a HER2 positive patient who has undergone neoadjuvant HER2-directed therapy, do you offer adjuvant trastuzumab if the surgical specimen is HER2 negative?

2 Answers available

What adjuvant therapy would you recommend to elderly patients with pT2N0 ER-/PR-/HER2+ breast cancer?

The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.

3 Answers available

How would you approach adjuvant therapy for a premenopausal female with HR+, HER2+ breast cancer with N1mic disease?

Stage T1bN1mic

2 Answers available

Would you offer neoadjuvant chemotherapy to premenopausal women with cT1cN0 HER2+ breast cancer?

2 Answers available

For a post-menopausal woman with a pT1c node negative HER2 positive breast cancer, does ER status influence your choice of adjuvant paclitaxel/trastuzumab versus docetaxel/carboplatin/trastuzumab?

This is a patient with a 1.8cm node negative HER2 positive tumor that is grade 3, high Ki67, and ER positive.

1 Answer available

In a patient with HR+HER2+ early breast cancer who is receiving adjuvant T-DM1 for residual disease, do you overlap endocrine therapy with T-DM1?

2 Answers available

Would you offer adjuvant HER 2 directed therapy for ER+/PR+/HER2+ pT1-T2 N0 papillary carcinoma of the breast?

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.

1 Answer available

How would you approach a patient with a HER2+ locoregional recurrence who did not receive prior systemic therapy?

Patient only had upfront surgery.

2 Answers available

Do you give bisphosphonates after completing adjuvant anti-HER2 therapy and chemotherapy for HER2+ breast cancer to reduce the risk of recurrence?

2 Answers available

Do you use trastuzumab for patients with localized HER2+ esophageal cancer after definitive chemoRT who are not surgical candidates?

Do you utilize it immediately following chemoRT or wait until disease progression?

3 Answers available

How would you approach a patient with metastatic ER+/Her2+ who has progressed on trastuzumab/pertuzumab + tamoxifen after being in remission for 4yrs?

2 Answers available

Should neoadjuvant chemotherapy be recommended for HER2+, clinically LN- breast cancer measuring 2-3cm?

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

2 Answers available

Do you offer neoadjuvant therapy to a postmenopausal cT1cN0 , HER2+, ER/PR+ breast IDC or recommend surgery first?

4 Answers available

For patients with HER2+ breast cancer with a resectable HER2+ local relapse within 12 months of completion of standard adjuvant therapy including 1 year of trastuzumab, what adjuvant therapy would you recommend?

Does hormone receptor status impact your decision?

2 Answers available

How do you use neratinib in HR+ HER2+ patients in the adjuvant setting if patients got adjuvant T-DM1 for residual disease after neoadjuvant therapy?

Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 inst...

1 Answer available

For triple positive metastatic breast cancer, is there a role for aromatase inhibitor + CDK 4/6 inhibitor with Her2 directed therapy in a patient that refuses chemotherapy?

Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6...

2 Answers available

Would you change treatment for denovo stage IV breast cancer Her 2 positive, ER positive in remission now with isolated brain metastasis?

The patient received THP and now is on maintenance HP when she developed CNS disease.

3 Answers available

How would you treat a young patient with good performance status who has de novo metastatic HR+ Her2+ inflammatory breast cancer with asymptomatic leptomeningeal and CNS parenchymal disease?

1 Answer available

In patients with stage II-III HER2+ breast cancer who were not treated with neoadjuvant therapy, without having knowledge of response to neoadjuvant therapy (i.e. pCR or not) after chemotherapy, what is your preferred adjuvant HER2 directed therapy?

Which patients should receive TDM-1, Trastuzumab+Pertuzumab or Trastuzumab alone?

2 Answers available

What is the role of neo-adjuvant chemotherapy in triple positive cT1c N0 breast cancer especially after recent data from KATHERINE trial?

Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab

1 Answer available

Would you offer a mid-treatment transition from transtuzumab to TDM-1 for a patient already on 1 year of adjuvant trastuzumab who met criteria for adjuvant TDM-1 based on the KATHERINE trial?

Any factors that would impact this decision (how far along adjuvant trastuzumab, disease characteristics, etc)?

2 Answers available

How do you choose a neoadjuvant therapy regimen for a patient with a triple negative breast cancer and a synchronous ER-/Her2+ breast cancer?

3 Answers available

Would you switch to TDM-1 in the adjuvant setting in HER-2 positive breast cancer patients with residual disease after neoadjuvant chemotherapy if neoadjuvant chemotherapy did not include anthracyclines?

Only a small subset (22-24%) of patients in Katherine trial received a non-anthracycline containing regimen.

1 Answer available

How do you utilize CDK 4/6 inhibitors in metastatic ER+ HER2+ breast cancer?

One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone. How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...

1 Answer available

How do you manage elderly women with high-risk HER2 positive disease with baseline low ejection fraction?

For example, in a patient > 70 years old?

1 Answer available

Will you offer adjuvant T-DM1 for patients with HER2+ breast cancer who have residual invasive disease following neoadjuvant therapy?

Will you incorporate the results from KATHERINE into clinical practice now?

3 Answers available

Would you consider adjuvant capecitabine as well as trastuzumab in a patient with ER/PR negative, HER2 positive breast cancer treated with neoadjuvant chemotherapy /trastuzumab/pertuzumab who has residual disease on path?

The CREATE-X trial did not include HER-2 positive patients but the ER-negative population benefited from capecitabine. Would you consider capecitabine...

1 Answer available

Do you consider multifocal disease an indication for chemotherapy with trastuzumab in patients with microinvasive Her2+/HR- breast cancer?

1 Answer available

What is the best second line treatment for a Her2+ metastatic breast cancer treated with frontline Taxol/Herceptin?

Would you do a pertuzumab-based regimen or T-DM1?

1 Answer available

Can carboplatin be omitted in neoadjuvant TCHP therapy in Her2+ breast cancer to avoid toxicity?

In light of the KATHERINE data- does this change your practice?

2 Answers available

Would you use paclitaxel and trastuzumab in ER negative, HER2+ breast cancer with micrometastases in a single node?

The NEJM 2015 paper by Tolaney et al only included 1.5% of patients with micrometastases.

1 Answer available

Would you use 6 months (instead of 12 months) of trastuzumab for locally advanced Her-2 positive breast cancer patients?

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

3 Answers available

What neoadjuvant chemotherapy regimen would you choose for a young patient with HER2 positive breast cancer with reduced ejection fraction?

Is there any evidence to use trastuzumab and pertuzumab without doxorubicin?

1 Answer available

Do you routinely check echocardiograms for patients getting HER2 directed therapy for metastatic breast cancer?

If so, how frequently?

5 Answers available

How do you assess the risk of cardiotoxicity from HER2+ agents?

1 Answer available

What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

1 Answer available

Would you consider stopping chemotherapy and continuing trastuzumab alone in a patient with metastatic HER2 positive GEJ cancer who had a complete response to chemotherapy and trastuzumab?

1 Answer available

How do you minimize the risk of cardiotoxicity in metastatic Her2 + breast cancer patients who are receiving trastuzumab and have a history of pre-existing cardiac disease?

1 Answer available

What is your preferred regimen for triple positive breast cancer with visceral metastasis while on adjuvant AI?

Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...

2 Answers available

What is your preferred regimen for triple positive breast cancer with bone only recurrence?

Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...

1 Answer available

In which Her2+ breast cancer patients would you recommend extended adjuvant therapy with neratinib?

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

1 Answer available

Would you use lapatinib to prevent recurrence of brain mets in a patient with recurrent brain-only mets from HER2+ breast cancer now rendered NED after radiation?

1 Answer available

Will you continue anti-estrogen therapy in the setting of initiation of TDM-1 for patients with metastatic ER+/HER2+ breast cancer?

1 Answer available

For women with metastatic HER2 + breast cancer who achieve a complete response, how long do you continue on HER2-directed therapies?

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?

3 Answers available

Is there a role for any of the CDK4/6 inhibitors in ER+/HER2+ or ER-/HER2+ metastatic breast cancer?

1 Answer available

Papers discussed in this category

Eur J Cancer, 2022 Sep 19

Selecting patients with HER2-low breast cancer: Getting out of the tangle.

Am J Transl Res, 2019 Sep 15

Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer.

Breast cancer research : BCR, 2009

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Cancer cell, 2012-10-16

The requirement for cyclin D function in tumor maintenance.

Cancer cell, 2016-03-14

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer discovery, 2016-07

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Cancer, 2015-12-15

Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.

Lancet (London, England), 2009-12-19

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

The Lancet. Oncology, 2014-06

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2012-11-08

Trastuzumab emtansine for HER2-positive advanced breast cancer.

J. Clin. Oncol.,

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.

The New England journal of medicine, 2012-01-12

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.

N Engl J Med,

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

N Engl J Med, 2019 Dec 11

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-01

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-06

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

Journal of gastrointestinal oncology, 2016-08

Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.

The Lancet. Oncology, 2014-10

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Lancet, 2010 Aug 19

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

N Engl J Med, 2020 May 29

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

J Clin Oncol, 2020 Mar 24

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

The New England journal of medicine, 2015-02-19

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Cochrane Database Syst Rev, 2008 Apr 16

Cardioprotective interventions for cancer patients receiving anthracyclines.

Eur. J. Cancer, 2013 May 22

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

N Engl J Med, 2015 Jan 8

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

The Lancet. Oncology, 2017-12

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

N. Engl. J. Med., 2017-07-13

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Lancet Oncol., 2016-06-01

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

N. Engl. J. Med.,

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

Lancet Oncol., 2018 Nov 06

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Lancet (London, England), 2014-07-12

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Lancet Oncol., 2012-01-01

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

The Lancet. Oncology, 2013-10

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Lancet Oncol., 2014-06-01

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Lancet Oncol., 2013 Dec 19

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

The Lancet. Oncology, 2017-06

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2019-02-14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

The Lancet. Oncology, 2016-03

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol., 2017 Feb 24

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Eur. J. Cancer, 2017 May 03

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.

N Engl J Med, 2011 Oct 6

Adjuvant trastuzumab in HER2-positive breast cancer.

Journal of neurosurgery, 2019-02-08

Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.

Breast cancer research and treatment, 2018-06

Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Breast, 2013 Dec 22

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

Breast, 2015 Oct 09

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Lancet,

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20

Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).

Curr Treat Options Oncol, 2019 Mar 14

Role of Bisphosphonates in Breast Cancer Therapy.

Breast Cancer, 2016 Feb 13

Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-02-15

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

The Lancet. Oncology, 2018-07

Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.

N. Engl. J. Med., 2019 Dec 11

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Anticancer Res.,

Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.

N Engl J Med, 2021 Sep 18

Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

The New England journal of medicine, 2018-07-12

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.

J. Clin. Oncol., 2019 Oct 16

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

The Lancet. Oncology, 2017-08

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Breast cancer research and treatment, 2014-11

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.

The oncologist, 2013

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-10

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Cancer Treat Rev, 2022 Mar 12

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

Breast Cancer Res. Treat., 2017 Mar 21

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Ann. Oncol., 2013-12-01

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

J. Clin. Oncol., 2009 Sep 28

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

Lancet Oncol, 2020 Apr 27

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-10

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Breast cancer research and treatment, 2011-10

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

J. Clin. Oncol., 2018 May 30

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Cancer Treat Rev, 2013 Jun 10

HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.

Clin Cancer Res, 2019 Sep 12

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.

J Clin Oncol, 2020 May 29

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Cancer, 2000-03-15

Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.

Front Oncol, 2020 Dec 03

Multiple Microinvasion Foci in Ductal Carcinoma Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome.

Annals of surgical oncology, 2018-07

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.

J Clin Oncol, 2018 Aug 14

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.

J Clin Oncol, 2020 Sep 16

Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10

Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Breast, 2011 Sep 08

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

Sci Rep, 2019 Dec 02

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.

J Clin Oncol, 2021 Feb 04

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Lancet Oncol., 2016-06-01

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

The Lancet. Oncology, 2019-04

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

J Natl Cancer Inst,

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Lancet Oncol, 2021 May 04

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Clin Cancer Res,

Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

Clin Breast Cancer, 2020 Oct 06

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

JAMA Oncol,

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J Thorac Oncol, 2020 Jan 13

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.

J Immunother Cancer, 2019 Jan 21

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

ESMO Open, 2021 Aug 31

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.

Cancer, 2019 Jul 18

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.

J Clin Oncol, 2021 Dec 10

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.

The Lancet. Oncology, 2014-02

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Front Oncol, 2018 Apr 17

Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.

Nature, 2021 Dec 15

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

N Engl J Med, 2022 Jan 19

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Gynecol Oncol, 2020 Nov 05

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Lancet,

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.

Br J Cancer, 2021 Jan 21

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Clin Cancer Res, 2022 Jan 19

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.

JCO Precis Oncol, 2019 Nov 15

Identifying Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.

N Engl J Med, 2022 Jun 05

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

Lancet, 2022 Dec 06

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.

JAMA Oncol,

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

Annals of surgical oncology, 2019-10

DCIS with Microinvasion: Is It In Situ or Invasive Disease?

Sci Rep, 2022 Jan 20

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.

The Lancet. Oncology, 2019-06

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

J Clin Oncol, 2020 Feb 14

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

N. Engl. J. Med., 2017 Jun 04

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

The New England journal of medicine, 2018-08-23

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Breast Cancer Res Treat, 2016 Feb 18

Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.

Mol Cancer Ther, 2018 Mar 28

Trastuzumab-Resistant HER2 Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Eur J Cancer, 2014 Aug 12

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

N Engl J Med, 2021 Jun 03

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Future Oncol, 2020 Nov 10

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

J Clin Oncol, 2022 Nov 15

Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.

Ann Gastroenterol, 2020 Jan-Feb

Clinical characteristics of colitis induced by taxane-based chemotherapy.

BMC Cancer, 2019 Oct 21

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.

JAMA Oncol, 2021 Sep 01

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

Clin Cancer Res, 2022 Feb 15

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).

Gastric Cancer, 2022 Jan 11

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).

J Cancer Res Clin Oncol, 2022 Aug 30

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

The New England journal of medicine, 2014-07-10

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

The New England journal of medicine, 2018-07-12

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med, 2021 Apr 22

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-05

Which threshold for ER positivity? a retrospective study based on 9639 patients.

J Clin Pathol, 2016 Sep 09

Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.

Breast Cancer, 2018 Jul 31

Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining.

Nature communications, 2023 Jun 07

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Scientific reports, 2023 May 31

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression.

Her2+

Questions discussed in this category

Papers discussed in this category

Related Topics